ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: axial spondyloarthritis

Treat to Target in axSpA

Samantha C. Shapiro, MD  |  November 29, 2022

PHILADELPHIA—Treat to target (T2T) is a common phrase in rheumatology these days—and a welcome one.1 Many of us are familiar with what T2T means in rheumatoid arthritis (RA), but we may be less sure of its meaning in axial spondyloarthritis (axSpA). At ACR Convergence 2022, Alexis Ogdie, MD, associate professor of medicine and epidemiology, University of…

Filed under:Axial SpondyloarthritisConditionsMeeting Reports Tagged with:ACR Convergence 2022ACR Convergence 2022 – ASAS Resource CenteraxSpA

An Evidence-Based Drug Update & Guidance for Rheumatologists

Samantha C. Shapiro, MD  |  August 14, 2022

ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…

Filed under:Drug UpdatesEducation & TrainingMeeting ReportsOther ACR meetings Tagged with:AAV FocusRheumACR Education ExchangeU.S. Food and Drug Administration (FDA)

Updates from the ACR’s Committee on Rheumatology Training & Workforce Issues

Jason Liebowitz, MD, FACR  |  June 17, 2022

The ACR’s Committee on Rheumatology Training & Workforce Issues helps young rheumatologists to become successful and find meaning in their work. Here is an update on the committee’s most recent accomplishments.

Filed under:Education & TrainingMeeting ReportsOther ACR meetings Tagged with:ACR Education Exchangeeducation and trainingonline educationTrainingWorkforce

New Tech Provides Insights Into the Pathogenesis of Psoriatic Arthritis

Maria de la Luz Garcia-Hernandez, PhD, & Christopher Ritchlin, MD, MPH  |  May 5, 2022

The etiology of psoriatic arthritis (PsA) is poorly understood but current evidence supports an interaction between genetic and environmental factors that coalesce to promote local tissue inflammation.1-3 The pivotal cytokines that underlie the local inflammatory response in a wide range of tissues are interleukin (IL) 23, IL-17 and tumor necrosis factor (TNF).4 The central contribution…

Filed under:ConditionsPsoriatic Arthritis Tagged with:psoriatic arthritis

Clinical Rheumatology Year in Review 2021

Samantha C. Shapiro, MD  |  November 22, 2021

ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersResearch RheumRheumatoid ArthritisVasculitis Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAClinicalClinical researchJAK inhibitorsjakinibsJanus Kinase InhibitorsKnee Osteoarthritis (OA)stepped exercise

Case Report: Reactive Arthritis Following COVID-19

Samuel C. Purkey, DO, James Z. Drew, MD, & Marcum Collins, MD  |  September 14, 2021

SARS-CoV-2, or COVID-19, is a complex disease entity that continues to evolve. Physicians, researchers and scientists alike have worked tirelessly to tackle this beast in its short existence; however, we are reminded daily that there is more to this virus than meets the eye. It is well known that COVID-19 can cause acute respiratory failure…

Filed under:Conditions Tagged with:COVID-19Reactive arthritisTenosynovitis

The Many Facets of JIA: Insights from Bench to Bedside for the Clinical Care of Patients with JIA

Jason Liebowitz, MD, FACR  |  July 18, 2021

Experts provide insights into spondyloarthropathy, temporomandibular joint involvement and imaging for pediatric patients with JIA.

Filed under:ConditionsMeeting ReportsPediatric Conditions Tagged with:imagingpatient carePediatricPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMspondyloarthropathytemporomandibular joint (TMJ)

Outcome Assessments: Measuring Global Disease Activity in Patients with Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  June 23, 2021

Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsPsoriatic Arthritis Tagged with:EULARoutcomeOutcome measurespsoriatic arthritis

TrifonenkoIvan / shutterstock.com

Artificial Intelligence Gives Rheumatologists an Assist

Mary Beth Nierengarten  |  June 14, 2021

As the novel coronavirus that causes COVID-19 spreads across the globe, innovative thinking is needed more than ever to counter the devastating effects on the physical and socioeconomic health of individuals and communities. Innovations in healthcare delivery not yet fully realized prior to the pandemic, such as the adoption of telehealth, are moving to the…

Filed under:ConditionsInformation TechnologyTechnology Tagged with:artificial intelligencebig dataimagingmachine learningTechnology

Therapeutic Drug Monitoring Has Little Value During Infliximab Induction

Reuters Staff  |  May 12, 2021

NEW YORK (Reuters Health)—Results of a randomized controlled trial do not support routine use of proactive therapeutic drug monitoring (TDM) during infliximab induction for improving disease remission rates in patients rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory diseases. Proactive therapeutic drug monitoring tailors biologic therapy to individual patients by measuring serum drug levels and…

Filed under:Conditions Tagged with:infliximabinfliximab inductiontherapeutic drug monitoring

  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 19
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences